Live Feeds
● LIVE Updated 2h ago · 13 sources tracked

ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer

Amgen's Imdelltra, in combination with AstraZeneca's Imfinzi, reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The combination extended median overall survival by 8.4 months to 21.1 months compared to Imfinzi alone. Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone. This treatment approach may become a new standard of care for this aggressive form of lung cancer.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Amgen's Imdelltra in combination with Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer.
  • ✓ The combination extended median overall survival by 8.4 months to 21.1 months compared to Imfinzi alone.
  • ✓ Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone.
  • ✓ The combination also reduced the risk of progression or death by 66%; median progression-free survival was 7.4 versus 1.9 months.
🛡️ Source Corroboration: 13 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

The latest update from Amgen's DeLLphi-305 study shows that Imdelltra in combination with Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for extensive-stage small cell lung cancer.

Live updates

  1. Amgen's Imdelltra drives massive survival benefit in small cell lung cancer

    Amgen's Imdelltra, in combination with AstraZeneca's Imfinzi, reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The combination extended median overall survival by 8.4 months to 21.1 months compared to Imfinzi alone. Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone. This treatment approach may become a new standard of care for this aggressive form of lung cancer.

    Why it matters

    Small cell lung cancer is a highly aggressive and deadly form of lung cancer. Current treatment options have limited efficacy, making new therapies urgently needed. The combination of Imdelltra and Imfinzi has shown significant promise in clinical trials, offering new hope for patients with this disease. The European Society for Medical Oncology (ESMO) recently presented data on this combination, generating significant interest and acclaim.

    What is confirmed

    • Amgen's Imdelltra in combination with Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer.
    • The combination extended median overall survival by 8.4 months to 21.1 months compared to Imfinzi alone.
    • Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone.
    • The combination also reduced the risk of progression or death by 66%; median progression-free survival was 7.4 versus 1.9 months.

    What to watch next

    • Future regulatory decisions on Imdelltra and Imfinzi combination.
    • Long-term follow-up data on the combination's efficacy and safety.
    • Potential impact on treatment guidelines and standard of care for small cell lung cancer.
    Sources used for this update (13)
    1. www.cnbc.com — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
    2. CNBC — Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
    3. Amgen — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
    4. NBC News — ‘Practice-changing’ new lung cancer immunotherapy improves survival
    5. Fierce Pharma — ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer
    6. Reuters — Amgen drug combined with immunotherapy extends survival in lung cancer trial
    7. Bloomberg.com — Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer
    8. www.amgen.com — IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH ...
    9. www.curetoday.com — 4 Lung Cancer Results From ESMO 2026 Patients Should Know
    10. finance.sina.com.cn — 又一次起立鼓掌！ESMO六大重磅研究透露癌症治疗新信号
    11. www.biospace.com — ESMO 2026: Amgen’s Imdelltra slashes death risk ... - BioSpace
    12. insights.citeline.com — ESMO 2026: Ovation As Imdelltra/Imfinzi Cuts Risk Of Death By ...
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community